ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1980

Tocilizumab in Giant Cell Arteritis: A Multicentre Open-Label Study in France

Alexis Regent1, Serge Redeker2, Alban Deroux3, Pierre Kieffer4, Kim Heang Ly5, Maxime Dougados6, Claire Larroche7, Loïc Guillevin1, Laurence Bouillet8, Olivier Espitia9, Nathalie Costedoat-Chalumeau10, Martin Soubrier11, Benoit Brihaye12, François Lifermann13, Guillaume Lefèvre14, Xavier Puéchal1, Luc Mouthon1, Eric Toussirot15 and GFEV and CRI, 1Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, 243 rue de l'isle, Ch Abbeville, Abbeville, France, 3Internal Medicine, CHU Grenoble, Grenoble, France, 4Hopital Emile Muller, Mulhouse Cedex 1, France, 5CHU de Limoges, Service de médecine interne, Limoges, France, 6Medicine Faculty, Paris-Descartes University, Paris, UPRES-EA 4058, Cochin Hospital, Rheumatology B, Paris, France, 7Internal Medicine, Paris, France, 8CHU, Grenoble, France, 9Internal Medicine, Nantes University Hospital, Nantes, France, 10Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, 11Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, 12Service de médecine interne et médecine polyvalente, Saint Quentin, France, 13CH Dax, Dax, France, 14Service de médecine interne, Centre National de Référence de la Sclérodermie Systémique, Hôpital Claude Huriez, CHRU Lille, Lille, France, 15Service de Rhumatologie, CHU J Minjoz, Besancon, France

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biologic drugs, giant cell arteritis, large vessel vasculitis and tocilizumab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Vasculitis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

To report the French experience on the efficacy and safety of tocilizumab (TCZ) in patients with giant cell arteritis (GCA) and outcome after treatment withdrawal.

Methods:

A retrospective multicenter study included patients treated with TCZ for their GCA. Treatment efficacy was evaluated at a clinical and biological level. Side effects and outcome after treatment withdrawal were also recorded.

Results:

Thirty-four patients (27 women and 7 males) aged 70.5±8.2 (mean±SD) were included. Diagnosis of GCA was based on the ACR criteria (30 patients) and/or on imaging abnormalities suggestive of GCA  (8 patients).  Treatment included glucocorticoids in all patients and another immunosuppressant before TCZ introduction in 20/34 patients (59%). TCZ (8 mg/kg monthly) was prescribed after a mean disease duration of 18 months (0-107) and patients were treated for a mean of 6.4±4.5 months. It was effective in all but 6 patients who still had mild symptoms while CRP was reduced from 40.4±45.6 mg/L to 1.5±1.8 mg/L (p<0.0001) and glucocorticoids were tapered from 26.3±13.8 to 10.3±8.3  (p<0,0001). One patient died from septic shock and TCZ was stopped in 3 patients for severe adverse events (tuberculous pericarditis, liver cytolysis and neutropenia). Among the 23 patients who stopped treatment (planned medical decision in 2O cases, side effects in 3 cases) eight patients experienced relapses occurring after a mean of 3.5±1.3 months and TCZ was started again in 5 of them.

Conclusion:

Under TCZ therapy, patients with GCA have a rapid and sustained improvement. However, side effects were noticeable and should be kept in mind in these patients. Questions remain regarding the suspensive nature of this treatment and this should be specifically addressed in future studies.


Disclosure: A. Regent, None; S. Redeker, None; A. Deroux, None; P. Kieffer, None; K. H. Ly, None; M. Dougados, None; C. Larroche, None; L. Guillevin, None; L. Bouillet, None; O. Espitia, None; N. Costedoat-Chalumeau, None; M. Soubrier, None; B. Brihaye, None; F. Lifermann, None; G. Lefèvre, None; X. Puéchal, None; L. Mouthon, None; E. Toussirot, None.

To cite this abstract in AMA style:

Regent A, Redeker S, Deroux A, Kieffer P, Ly KH, Dougados M, Larroche C, Guillevin L, Bouillet L, Espitia O, Costedoat-Chalumeau N, Soubrier M, Brihaye B, Lifermann F, Lefèvre G, Puéchal X, Mouthon L, Toussirot E. Tocilizumab in Giant Cell Arteritis: A Multicentre Open-Label Study in France [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/tocilizumab-in-giant-cell-arteritis-a-multicentre-open-label-study-in-france/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tocilizumab-in-giant-cell-arteritis-a-multicentre-open-label-study-in-france/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology